Jump to content

Genedata and Merck Co-Develop A Digital Platform For Translational and Clinical Biomarker Research

Genedata delivers fully validated cloud-based enterprise solution for integration, management & analysis of clinical, biomarker, NGS, & digital pathology data from public & clinical studies to enable AI-driven development of next generation therapeutics

October 23, 2019
Basel, Switzerland

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the successful completion of a multi-year software development project in close collaboration with Merck, a leading science and technology company.

Fulfilling Merck’s expressed need for a large-scale data management and analysis platform to facilitate molecular profiling of large cohorts of patients by a wide range of geographically dispersed users in a secure and validated software environment, Genedata developed new features to enhance the power of Genedata Profiler®, its leading software for translational and clinical research. Some feature highlights include:

  • New end-to-end, digital pathology workflow system that enables the analysis and visualization of data from major imaging instrument vendors.
  • Extensive data capture system that also integrates digital pathology, multi-omic, clinical, and biomarker data to provide a holistic data view serving as a basis for artificial intelligence approaches.
  • Automated, compliant data workflows for neoepitope prediction, tumor mutational burden analysis, and other immuno-oncology specific workflows using NGS data.
  • Workflow systems which can be deployed in a compliant environment for reproducible and trackable clinical decisions.
  • Highly scalable data management system which allows global multidisciplinary teams to collaborate in a secure and controlled environment.
  • Enhanced data governance, provenance and metadata support of clinical data, including file deletion upon revocation of patients’ informed consent.
  • Enhanced deployment options on the Amazon Web Services® cloud to facilitate auto-scaling, monitoring and continuous validation.
  • Bioinformatics interfaces for holistic assessment of different types of biomarker data enabling differentially skilled user groups to assess biomarker patterns by appropriate methods – from simple statistics to AI and machine learning.

“Working closely with Genedata, we have generated a digital biomarker research platform that will enable Merck scientists to better utilize clinical and translational data to generate innovative ideas for new biomarkers and drug targets,” said Joern Peter Halle, Head of Immuno-oncology and External Innovation. “Merck Healthcare is fully committed to drive R&D digitalization to foster the development of Precision Medicines for the benefit of patients. The Genedata platform is an important cornerstone in enhancing the analytical capabilities of our teams with cutting-edge digital technology.”

“We are very pleased with the first milestone of this collaboration with Merck, a global leader in the biopharmaceutical industry,” said Dr. Othmar Pfannes, CEO of Genedata. “The project delivered a state of the art, compliant Genedata Profiler platform, including best-practice pipelines for processing and analysis of NGS and immunohistochemistry data from clinical trials, with the goal to develop more efficient treatments. We are committed to continue developing Genedata Profiler as the leading platform for improving clinical and translational research.”

Genedata and Merck plan to continue the collaboration with a view to develop the software platform to further enhance its capabilities to integrate different types of ‘omics data and to make use of the newest AI technology to generate deeper biological insights and better therapeutics.

About Genedata Profiler
Genedata Profiler enables biopharmaceutical research organizations to efficiently discover and develop precision medicines for cancer patients by streamlining data integration and analysis processes in translational and clinical research, while maintaining full compliance with data security and data privacy requirements. The newly enhanced Genedata Profiler platform is now available for license by third parties.

About Genedata

Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube


Allison Kurz
Public Relations


The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

The Genedata platform is an important cornerstone in enhancing the analytical capabilities of our teams with cutting-edge digital technology. It will enable Merck scientists to better utilize clinical and translational data to generate innovative ideas for new biomarkers and drug targets

Joern Peter Halle
Head of Immuno-oncology and External Innovation